Selective Serotonin Reuptake Inhibitor Discontinuation for Psilocybin Treatment and Contributions to Alcohol Addiction Relapse
Mark A Frye, Balwinder Singh, Scott Breitinger, Tyler Oesterle
The Journal of Clinical Psychiatry August 25, 2024 DOI: 10.4088/jcp.24cr15378 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Case study Case report Peer reviewed |
|---|---|
| Sample size | 1 |
| Population | A man with alcohol use disorder |
| Interventions | SSRI naltrexone |
| Topics | Addiction Anxiety Psilocybin Serotonin |
| Keywords | Discontinuation Serotonin uptake inhibitors Serotonin reuptake inhibitor Hallucinogen Psychotherapist Pharmacology Fluoxetine Antidepressant Receptor |
| Citations | 2 |
| Key findings | Discontinuing an SSRI to participate in a psilocybin ceremony may contribute to relapse in a person with AUD who had been stable on medication. |
Abstract
A man with AUD achieves sobriety on treatment with an SSRI and naltrexone, but then stops taking the SSRI to participate in a psilocybin “ceremony.” What factors contributed to his subsequent relapse to alcohol use?